Join us for an educational dinner program in Nashville:

Current Thinking in Dry Eye Disease:
Contemporary Perspectives on a Complex Condition


David Kading, OD, FAAO, FCLSA
Optometric Insights
Seattle, Washington

Jessilin Quint, OD, MBA, FAAO
Smart Eye Care
Augusta, Maine


Thursday, June 20, 2024

Registration: 6:45 PM CT  
Program: 7:00 PM CT 


Morton's The Steakhouse
618 Church St 
Nashville, TN 37219


MIEBO® (perfluorohexyloctane ophthalmic solution) is indicated for the treatment of the signs and symptoms of dry eye disease.


  • MIEBO should not be administered while wearing contact lenses. Contact lenses should be removed before use and for at least 30 minutes after administration of MIEBO
  • Instruct patients to instill one drop of MIEBO into each eye four times daily
  • The safety and efficacy in pediatric patients below the age of 18 have not been established
  • The most common ocular adverse reaction was blurred vision (1% to 3% of patients reported blurred vision and conjunctival redness)

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit or call 1-800-FDA-1088.

CLICK HERE for full Prescribing Information for MIEBO.

Reference: 1. MIEBO Prescribing Information. Bausch & Lomb Incorporated.


Xiidra® (lifitegrast ophthalmic solution) 5% is indicated for the treatment of signs and symptoms of dry eye disease (DED).


  • Xiidra is contraindicated in patients with known hypersensitivity to lifitegrast or to any of the other ingredients.
  • In clinical trials, the most common adverse reactions reported in 5-25% of patients were instillation site irritation, dysgeusia and reduced visual acuity. Other adverse reactions reported in 1% to 5% of the patients were blurred vision, conjunctival hyperemia, eye irritation, headache, increased lacrimation, eye discharge, eye discomfort, eye pruritus and sinusitis.
  • To avoid the potential for eye injury or contamination of the solution, patients should not touch the tip of the single-use container to their eye or to any surface.
  • Contact lenses should be removed prior to the administration of Xiidra and may be reinserted 15 minutes following administration.
  • Safety and efficacy in pediatric patients below the age of 17 years have not been established.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit or call 1-800-FDA-1088.

CLICK HERE for full Prescribing Information for Xiidra.

This is an educational program sponsored by Bausch + Lomb. No CE/CME will be provided for this program. Only physicians and healthcare professionals involved in providing patient care or product recommendations may attend this educational program. Attendance by guests and spouses is not permitted.

Please note: Alcohol will not be provided by Bausch + Lomb at this event. If an attendee chooses to purchase alcohol, this must be charged to and paid for by the attendee directly and will not be paid for or subsidized by Bausch + Lomb. Your name and the value of any meal/refreshments may be reported as required by federal and state laws. You must notify the Bausch + Lomb representative upon sign-in if you maintain a license to practice medicine in Minnesota or Vermont.

Sponsored by


©2024 Bausch + Lomb MBO.0220.USA.24
All Information pertains to the U.S. only, unless otherwise indicated.

Brought to you by